Fig. 5: The R1441C LRRK2 mutation also decreases the physiological αSyn T:M ratio.

a Representative WBs of patient lines bearing the LRRK2 R1441C mutation show significantly decreased αSyn T:M ratios. Treatment with either a LRRK2 kinase inhibitor (MLi2) (b) or an SCD inhibitor (5b) (c) restored the physiologic T:M ratio WT levels d. e R1441C also increases pSer129 phosphorylation of αSyn. f Inhibiting LRRK2 kinase or g inhibiting SCD reduced pSer129 levels. h Quantifying the ratio of pSer129 to total αSyn (for both d and h, N ≥ 3 independent experiments; each dot is an independent replicate sample; one-way ANOVA with Tukey’s post hoc test; error bars = SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).